Maiorano, B.A.; Lorusso, D.; Maiorano, M.F.P.; Ciardiello, D.; Parrella, P.; Petracca, A.; Cormio, G.; Maiello, E.
The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. Int. J. Mol. Sci. 2022, 23, 3871.
https://doi.org/10.3390/ijms23073871
AMA Style
Maiorano BA, Lorusso D, Maiorano MFP, Ciardiello D, Parrella P, Petracca A, Cormio G, Maiello E.
The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. International Journal of Molecular Sciences. 2022; 23(7):3871.
https://doi.org/10.3390/ijms23073871
Chicago/Turabian Style
Maiorano, Brigida Anna, Domenica Lorusso, Mauro Francesco Pio Maiorano, Davide Ciardiello, Paola Parrella, Antonio Petracca, Gennaro Cormio, and Evaristo Maiello.
2022. "The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy" International Journal of Molecular Sciences 23, no. 7: 3871.
https://doi.org/10.3390/ijms23073871
APA Style
Maiorano, B. A., Lorusso, D., Maiorano, M. F. P., Ciardiello, D., Parrella, P., Petracca, A., Cormio, G., & Maiello, E.
(2022). The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. International Journal of Molecular Sciences, 23(7), 3871.
https://doi.org/10.3390/ijms23073871
